 |
 |
 |
 |
 |
 |
 |
Industry advisory board
Montagu Newhall Associates has surrounded itself with some of the best venture capitalists and industry experts in the business. The management team is honored by their involvement and privileged to have their counsel. The fact that each member of the Advisory Board is an investor in Montagu Newhall Associates’ funds is the best validation of the products that have been created.
C. Richard Kramlich
Co-Founder & General Partner, New Enterprise Associates
Dick has more than 35 years of venture capital investment experience. Dick focuses on a broad range of technically oriented companies. Present board memberships include Fabric7 Systems, Financial Engines, Force10 Networks, Foveon, Informative, Visual Edge Technology, Tabula, Nexthop Techologies, Xoom Corporation and Zhone Technologies (NASDAQ: ZHNE). Previous board memberships include among others, 3Com Corporation (NASDAQ: COMS), Ascend Communications (acquired by Lucent Technologies), Dallas Semiconductor (acquired by Maxim Integrated Products), Healtheon/WedMD (NASDAQ: HLTH), Immunex (acquired by Amgen), InfoGear (acquired by Cisco Systems), Juniper Networks (NASDAQ: JNPR), Macromedia (NASDAQ: MACR) acquired by Adobe, Net Solve (NASDAQ: NTSL) acquired by Cisco Systems, Decru (acquired by Network Appliance), Silicon Graphics, and Semiconductor Manufacturing International (SMIC) (NYSE: SMI). He was recently Chairman and President of the National Venture Capital Association.
Prior to joining NEA, Dick was a General Partner of Arthur Rock & Associates and Executive Vice President of Gardner & Preston Moss. He received a Masters in Business Administration from the Harvard University Graduate School of Business and a Bachelor of Science in History from Northwestern University. He has received a Lifetime Achievement Award from the National Venture Capital Association and the University of California-Haas School of Business. He and his wife Pam are noted collectors of Media Art.
Charles W. Newhall III
Co-Founder & General Partner, New Enterprise Associates
Chuck is a Co-Founder and General Partner of NEA. His investment activities focus on healthcare services, healthcare information services and biopharmaceutical companies. His board memberships include CompHealth, Concurrent Pharmaceuticals, ElderHealth, Hospital Partners of America, Sensors for Medicine & Science, TargetRx, Trine Pharmaceuticals and Vela Pharmaceuticals. His prior board memberships include among others, AMERIGROUP, Caremark, Chomerics, Genetic Therapy, Life Technologies, PatientKeeper, Russ Pharmaceuticals, Scandipharm, Sepracor, Surgical Health and Zymark Corporation. He is a Founder of the Mid-Atlantic Venture Association.
Before co-founding NEA, Chuck was a Vice President with T. Rowe Price Associates and Vice President of their New Horizons Fund. He received his MBA from the Harvard University Graduate School of Business and his BA in English Literature with honors from the University of Pennsylvania.
Jim Blair
General Partner, Domain Associates
Mr. Blair has been a Partner of Domain since its founding in 1985. Present board memberships include Cadence Pharmaceuticals, Cell Biosciences, Five Prime Therapeutics, GenVault, NeuroPace, Novacea, NuVasive, Pharmion and Volcano. Mr. Blair has over thirty-five years experience with venture and emerging growth companies. In the course of this experience, he has been involved in the creation and successful development at the Board level of over forty life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Dura Pharmaceuticals, GeneOhm Sciences and Molecular Dynamics. A former managing director of Rothschild Inc., Mr. Blair was directly involved at a senior level with Rothschild/New Court venture capital activities from 1978 to 1985. From 1969 to 1978, he was associated with F.S. Smithers and Co. and White, Weld and Co., two investment banking firms actively involved with new ventures and emerging growth companies. From 1961 to 1969, Mr. Blair was an engineering manager with RCA Corporation, during which time he received a David Sarnoff Fellowship. He currently serves on the Board of Directors of the Prostate Cancer Foundation, and he is on the Advisory Boards of the Department of Molecular Biology at Princeton University and the Department of Biomedical Engineering at the University of Pennsylvania. Mr. Blair received a B.S.E. from Princeton University and along with an M.S.E. and Ph.D. from the University of Pennsylvania.
Jim Swartz
Founder, Accel Partners
Jim Swartz has been active in venture capital since the early 1970's. Experienced
in the operating needs of young companies, he particularly enjoys working
with start-up teams that are defining new industries. He has served as a Director
for over forty successful companies and has been closely involved as lead
investor with the emergence of numerous industry pioneering firms including Avici
Systems, BroadBand Technologies, FastForward/Inktomi, FVC.com,
Illustra/Informix, Medical Care America, Netopia, PictureTel, Polycom, Remedy
Corporation and Ungermann-Bass.
Current private company directorships include Gen3
Partners, InGenuity Systems, Leapstone, MetraTech, RGB
Networks , Riverbed Technology,
and Transera Communications.
In addition, Jim is working closely with the Accel Europe team as a founder/mentor
of Accel's European business.
Before founding Accel Partners, Jim was founding General Partner of Adler & Company,
which he started with Fred Adler in 1978 after his tenure as a Vice President
of Citicorp Venture Capital. Early in his career Jim worked as a management consultant,
entering the venture capital industry in 1972.
Active in industry affairs, Jim is a former Director and Chairman of the National
Venture Capital Association and a former President of the New York Venture Capital
Forum. He is a graduate of Harvard University with a concentration in Engineering
Sciences and Applied Physics (he mostly remembers something about playing football)
and holds an M.S. in Industrial Administration from Carnegie Mellon University.
Ryan Drant
General Partner, New Enterprise Associates
Ryan joined NEA in 1996 as a Principal, became a Partner in 2002, and a General Partner in 2004. He specializes in healthcare investments in the specialty pharma, medical device and healthcare services sectors. Present board memberships include BENU, Concentric Medical, ExploraMed II, ForHealth Technologies, FoxHollow Technologies (NASDAQ: FOXH), Intrinsic Therapeutics, PatientKeeper, ProVation Medical, Saturn Pharmaceuticals, Spine Wave, and Viacor. Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.) and Proxima Therapeutics (acquired by Cytyc Corporation), and Ryan co-led NEA’s investment in Xcel Pharmaceuticals (acquired by Valeant Pharmaceuticals, Inc.).
Prior to joining NEA, Ryan was with the Health Care Investment Banking Group of Alex. Brown & Sons in San Francisco where he focused primarily on the medical device, biopharmaceutical and healthcare services areas. Previously, he worked in the San Francisco office of Arthur Andersen & Co. Ryan received a BA from Stanford University.
Bob More
Partner, Domain Associates
Mr. More joined Domain as a Kauffman Fellow in 1996, and he became a Partner in 2000. Present board memberships include Esprit Pharma, Glaukos, Novalar Pharmaceuticals, NovaCardia, OmniSonics Medical Technologies, TargetRx and Windward Medical. Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation) and Onux Medical (acquired by C.R. Bard). Mr. More was also responsible for Domain’s investment in IntraLase (NASDAQ:ILSE). Additionally, Mr. More serves as a founding board member for Kauffman Fellows Program and serves as an Advisory Board member for Montagu Newhall Associates, Fresh Tracks Capital, Okapi Ventures and the Medical Industry Group, NVCA.
From 1997-1998, Mr. More served as the Chief Operating Officer of Small Molecule Therapeutics, a Domain portfolio company subsequently purchased by Morphochem AG. From 1992 to 1995, Mr. More was with Pharmacia Biotech in sales. Prior to joining Pharmacia, Mr. More held a research position at Somatogen, a company developing a recombinant blood substitute that was subsequently bought by Baxter. While attending business school, Mr. More worked with MedVest, an early-stage venture group in Washington, D.C. Mr. More received a B.A. from Middlebury college and an M.B.A. from the Darden School of Business Administration at the University of Virginia.
Barry Eggers
Co-Founder & General Partner, Lightspeed Venture Partners
Barry is a founding partner of Lightspeed Venture Partners, and focuses primarily on enterprise infrastructure, digital media, networking, and semiconductor investments. He has nine years of venture capital experience and ten years of operating experience.
Prior to joining Weiss, Peck & Greer Venture Partners in 1997, Barry was Director of Business Development at Cisco Systems, where he led several acquisitions and integrations. While at Cisco, Barry also was responsible for establishing several of the company's largest technology partnerships and distribution channels with OEMs, Service Providers, and VARs. Barry holds a BA in Economics and Business from UCLA and an MBA from the Stanford Graduate School of Business.
